Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000310453 | SCV000340981 | uncertain significance | not provided | 2016-04-12 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001052444 | SCV001216654 | benign | Mowat-Wilson syndrome | 2023-08-27 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001052444 | SCV002045629 | uncertain significance | Mowat-Wilson syndrome | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002392806 | SCV002701535 | uncertain significance | Inborn genetic diseases | 2022-03-10 | criteria provided, single submitter | clinical testing | The c.1446A>C (p.E482D) alteration is located in exon 8 (coding exon 7) of the ZEB2 gene. This alteration results from a A to C substitution at nucleotide position 1446, causing the glutamic acid (E) at amino acid position 482 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |